Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-24T02:39:30.116Z Has data issue: false hasContentIssue false
  • English
  • Français

Polypharmacy and relapse of schizophrenia: are they related?

Published online by Cambridge University Press:  01 September 2022

R. Softic ,
S. Osmanovic  and
N. Becarevic
R. Softic*
Affiliation:
University Clinical Center Tuzla, Of Psychiatry, Tuzla, Bosnia and Herzegovina
S. Osmanovic
Affiliation:
Health Center Brčko, Of Psychiatry, Brčko, Bosnia and Herzegovina
N. Becarevic
Affiliation:
University Clinical Center Tuzla, Of Psychiatry, Tuzla, Bosnia and Herzegovina
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Polypharmacy can be the cause of deliberate discontinuation of medication and consequent relapse of schizophrenia.

Objectives

To establish the one-year rate of relapse in the patients with schizophrenia with regard to monotherapy or polypharmacy.

Methods

The sample of all hospitalized patients with schizophrenia in a five-year period was analyzed. Descriptive statistics were used.

Results

Total of 87 participants (57 women), the median age was 43 years. Antipsychotic monotherapy was used in 31 (35.6%) of the participants. In one year period, 32 (36.8%) of all participants had a relapse. Prior to relapse, significantly more participants were treated with polypharmacy (p<0,05).

Conclusions

Antipsychotic polypharmacy is related to a higher rate of relapse in patients with schizophrenia.

Disclosure

No significant relationships.

Keywords

schizophréniaRelapsePolypharmacy
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S765
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.